Evidence map›Paper›PMID 40715064›Full record

ArticleNature communications2025

Large-scale RNA-Seq mining reveals ciclopirox olamine induces TDP-43 cryptic exons.

Irika R Sinha, Parker S Sandal, Holly Spence, Grace D Burns, Aswathy Peethambaran Mallika, Fatemeh Abbasinejad, Katherine E Irwin, Anna Lourdes F Cruz, Vania Wang, Shaelyn R Marx and 5 more

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. TDP-43: [GU]-ardian of the transcriptome.Molecular neurodegeneration · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Irika R Sinha *Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0001-6440-7019
Parker S Sandal *Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0009-0006-4452-2400
Holly SpenceInstitute of Medical Sciences, University of Aberdeen, Aberdeen, UK.ORCID http://orcid.org/0000-0002-1628-6790
Grace D BurnsDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Aswathy Peethambaran MallikaDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0003-0303-5156
Fatemeh AbbasinejadScientific Software Engineering Center, Johns Hopkins University, Baltimore, MD, USA.ORCID http://orcid.org/0009-0006-3239-7112
Katherine E IrwinDepartment of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Anna Lourdes F CruzDepartment of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Vania WangDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Shaelyn R MarxDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Josué Llamas RodríguezDepartment of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Ben LangmeadKavli Neuroscience Discovery Institute, Johns Hopkins University, Baltimore, MD, USA.ORCID http://orcid.org/0000-0003-2437-1976
Jenna M GregoryInstitute of Medical Sciences, University of Aberdeen, Aberdeen, UK.ORCID http://orcid.org/0000-0003-3337-4079
Philip C WongDepartment of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0001-8162-3274
Jonathan P LingDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. jling@jhu.edu.ORCID http://orcid.org/0000-0003-1927-9729

Funding

Research Education ComponentP30AG066507 · NIA · JOHNS HOPKINS UNIVERSITY · PI Corinne Pettigrew · 2020 to 2026
$29.3M
The Physical Biology of Neurodegeneration in Sporadic Amyotrophic Lateral Sclerosis/Frontotemporal DementiaR01NS127186 · NINDS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI HOLT, LIAM J, PHATNANI, HEMALI · 2021 to 2025
$8.2M
T32: Predoctoral and Postdoctoral Training Program in Nanotechnology for Cancer ResearchT32CA153952 · NCI · JOHNS HOPKINS UNIVERSITY · PI Denis Wirtz · 2015 to 2026
$3.5M
TDP-43 Proteinopathy in ALS-FTD: Mechanism, Target Validation and BiomarkerR01NS095969 · NINDS · JOHNS HOPKINS UNIVERSITY · PI PHILIP C WONG · 2016 to 2026
$2.4M
Functional Validation of TDP-43 splicing repression for frontotemporal degenerationUH3NS115608 · NINDS · JOHNS HOPKINS UNIVERSITY · PI WONG, PHILIP C · 2021 to 2022
$2.2M
Generation and characterization of a mouse model exhibiting beta-amyloidosis and tauopathy with nuclear depletion of TDP-43R33NS115161 · NINDS · JOHNS HOPKINS UNIVERSITY · PI WONG, PHILIP C · 2022 to 2023
$1.3M
Characterizing novel Mixed Etiology Dementia models compromised for TDP-43 functionF31NS135935 · NINDS · JOHNS HOPKINS UNIVERSITY · PI Grace D Burns · 2024 to 2026
$125k
FDA HHS U01 FD008129National Science Foundation (NSF) DGE2139757National Science Foundation (NSF) OAC1920103NCI NIH HHS T32 CA153952NIA NIH HHS P30 AG066507NINDS NIH HHS F31 NS135935NINDS NIH HHS R01 NS095969NINDS NIH HHS R01 NS127186NINDS NIH HHS R33 NS115161NINDS NIH HHS UH3 NS115608U.S. Department of Health & Human Services | National Institutes of Health (NIH) R01NS095969U.S. Department of Health & Human Services | National Institutes of Health (NIH) R01NS127186U.S. Department of Health & Human Services | National Institutes of Health (NIH) R33NS115161U.S. Department of Health & Human Services | National Institutes of Health (NIH) UH3NS115608U.S. Department of Health & Human Services | U.S. Food and Drug Administration (U.S. Food & Drug Administration) 1U01FD008129
6 · The paper itself

Abstract

Nuclear clearance and cytoplasmic aggregation of TDP-43, initially identified in ALS-FTD, are hallmark pathological features observed across a spectrum of neurodegenerative diseases. We previously found that TDP-43 loss-of-function leads to transcriptome-wide inclusion of deleterious cryptic exons, a signature detected in presymptomatic biofluids and postmortem ALS-FTD brain tissue, but the upstream mechanisms that lead to TDP-43 dysregulation remain unclear. Here, we developed a web-based resource (SnapMine) to determine the levels of TDP-43 cryptic exon inclusion across hundreds of thousands of publicly available RNA sequencing datasets. We established cryptic exon inclusion levels across a variety of human cells and tissues to provide ground truth references for future studies on TDP-43 dysregulation. We then explored studies that were entirely unrelated to TDP-43 or neurodegeneration and found that ciclopirox olamine (CPX), an FDA-approved antifungal, can trigger the inclusion of TDP-43-associated cryptic exons in a variety of mouse and human primary cells. CPX induction of cryptic exons arises from heavy metal toxicity and oxidative stress, suggesting that similar vulnerabilities could play a role in neurodegeneration. Our work demonstrates how diverse datasets can be linked through common biological features and underscores how public archives of sequencing data remain a vastly underutilized resource with tremendous potential for uncovering novel insights into complex biological mechanisms and diseases.

Indexed as

CiclopiroxDNA-Binding ProteinsExonsAmyotrophic Lateral SclerosisAnimalsHumansMiceRNA-SeqCiclopiroxDNA-Binding ProteinsTARDBP protein, human

Identifiers

PMID40715064
PMCPMC12297563

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.